CN Healthy Food Tech Group Corp. (UCFI) reported 2025 revenue of $27.8 million, up 144.6% from $11.3 million, and net income of $8.4 million, up 110.5% from $4.0 million. The company attributed higher revenue to four additional months of revenue-generating activity, promotions and new product launches.
Operating activities used $9.0 million in cash in 2025, compared with $42.1 million provided in 2024. As of December 31, 2025, cash and cash equivalents were $33,013,749 and the net working capital surplus was $12,280,831; management said existing cash would be sufficient for working capital and capital expenditures over at least the next 12 months. Nasdaq halted trading after receiving notice that the CSRC had not completed its review of the U.S. listing; the company said it had provided additional documentation and was awaiting further information.
Management reported three outstanding promissory notes in default and negotiations with creditors, while concluding there were no material doubts about its ability to continue as a going concern. It also concluded disclosure controls failed to operate effectively and internal control over financial reporting was ineffective as of December 31, 2025, citing three critical deficiencies.
CN Healthy Food Tech Group Corp. (UCFI) says Nasdaq’s Hearings Panel approved its continued listing, subject to conditions including a one-year Discretionary Panel Monitor. The Panel found that the company’s disclosure about the status of its China Securities Regulatory Commission application omitted material information, while noting that the omission did not concern its finances or business operations.
UCFI says it implemented remedial measures and committed to maintain them for three years. They include engaging a new PRC law firm as compliance advisor, establishing a Compliance and Risk Management Department, adopting disclosure controls, and maintaining a seven-member board with four independent directors. If Nasdaq determines during the monitoring period that UCFI fails a listing standard, the company will not be able to submit a compliance plan or receive additional time or an otherwise available cure period; Nasdaq would promptly issue a Staff Delisting Determination. UCFI does not intend to request review, and says trading resumption is not assured.
CN Healthy Food Tech Group Corp. reported Q2 2026 net revenue of $8.73 million, up 17.1% year over year, and six‑month 2026 revenue of $14.56 million, up 21.6%. Gross profit for the first half rose 51.6% to $10.61 million, reflecting lower unit costs after bringing core production in‑house.
Despite stronger operations, six‑month net income declined 25.6% to $2.75 million, driven by a $436,961 CSRC administrative penalty and $335,908 of default interest on three promissory notes. Operating cash flow was a $10.63 million outflow, mainly as large customer prepayments were worked down and inventory and supplier prepayments increased. Cash stood at $23.32 million, almost entirely in PRC banks, supporting a working capital surplus of $15.79 million.
As of June 30, 2026, $3.47 million of promissory notes remained in default at a 15% default rate and carry conversion features that could dilute shareholders. The company’s shares and warrants remain subject to a Nasdaq trading halt, and a July 2026 Nasdaq delisting determination is under appeal. Management concluded that, considering available cash and planned intra‑group financing from its PRC subsidiary, substantial doubt about going concern has been alleviated, though multiple material weaknesses in internal controls persist.
CN Healthy Food Tech Group Corp. reports that Nasdaq Listing Qualifications Staff has determined to delist its common stock and warrants from The Nasdaq Stock Market. The action is based on Nasdaq’s discretionary authority under Listing Rule 5101 and alleged issues under Listing Rules 5205(e) and 5250(a)(1), following disclosures about the status of a review process with the China Securities Regulatory Commission.
The company plans to timely request a hearing before a Nasdaq hearings panel by July 23, 2026. A timely request would stay any suspension of the securities pending the panel’s decision, but the current trading halt on both the common stock and warrants will remain in place during the appeal. The company cautions there is no assurance it will prevail or that its securities will resume trading or remain listed on Nasdaq, and notes that an adverse unanimous panel decision could result in immediate delisting.